within Pharmacolibrary.Drugs.ATC.C;

model C02KD01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0005333333333333334,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0024,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01633333333333333,
    Tlag           = 1260,            
    Vdp             = 0.003,
    k12             = 26,
    k21             = 26
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02KD01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ketanserin is a quinazoline-derived serotonin (5-HT2A) receptor antagonist with additional alpha-1 adrenergic blocking effects. It was developed and used primarily as an antihypertensive agent for the treatment of high blood pressure, but is not widely approved or used currently due to availability of newer antihypertensives and concerns about side effects.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy male volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Heykants, J, et al., &amp; Mills, J (1986). Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. <i>European journal of clinical pharmacology</i> 31(3) 343–350. DOI:<a href=\"https://doi.org/10.1007/BF00981135\">10.1007/BF00981135</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3792432/\">https://pubmed.ncbi.nlm.nih.gov/3792432</a></p></li><li><p>Persson, B, et al., &amp; Hedner, T (1991). Clinical pharmacokinetics of ketanserin. <i>Clinical pharmacokinetics</i> 20(4) 263–279. DOI:<a href=\"https://doi.org/10.2165/00003088-199120040-00002\">10.2165/00003088-199120040-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2036747/\">https://pubmed.ncbi.nlm.nih.gov/2036747</a></p></li><li><p>Reimann, IW, et al., &amp; Klotz, U (1983). Pharmacokinetics of ketanserin in man. <i>European journal of clinical pharmacology</i> 25(1) 73–76. DOI:<a href=\"https://doi.org/10.1007/BF00544018\">10.1007/BF00544018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6617728/\">https://pubmed.ncbi.nlm.nih.gov/6617728</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02KD01;
